Back to Peptides

5-Amino-1MQ

Metabolic & Weight Loss

5-Amino-1MQ is a lipophilic small molecule that inhibits the enzyme NNMT, enhancing energy metabolism and promoting fat loss while preserving lean muscle. Preclinical studies show notable effects on adipose tissue, cholesterol reduction, and enhanced mitochondrial function. It is being explored in preclinical models for potential fat loss and metabolic modulation.

Administration
Oral
mg capsule/tablet
Daily Range
50–150 mg Oral
Daily
Standard Dose
100 mg
Cycle
4–8 weeks
then reassess
NNMT inhibitoradipose metabolismfat lossmuscle preservationNAD+body recomposition

Dosing Guide

In murine studies, doses ranged from 10–50 mg/kg/day via oral or injection routes. These are not approved or validated in humans.

Oral

Daily
PhaseDose
Weeks 1–250 mg
Weeks 3–4100 mg
Weeks 5+150 mg

Frequency & Cycling

Oral

Cycle 20–30 days on, followed by 1–2 weeks off to maintain response. Benefits may diminish beyond 8–12 weeks continuous use due to tolerance development. Consider pairing with NAD+ protocols cautiously.

💊 Quick Start

Potential Benefits & Use Cases

5-Amino-1MQ is an experimental research compound and not approved for human use.
Reduces white adipose tissue mass by 35% and decreases adipocyte size by 30% in diet-induced obese mice (preclinical)
Elevates NAD+ levels and activates SIRT1 in preclinical studies (preclinical)
Enhances grip strength in aged mice when combined with exercise (preclinical)
Increases daily running distances with less endurance decline vs exercise alone (preclinical)
Clinical data Strong preclinical Limited data

Mechanism of Action

→Inhibits nicotinamide N-methyltransferase (NNMT)
→Reduces fat cell size and promotes adipose tissue metabolism
→Preserves muscle mass during caloric restriction
→May enhance NAD+ salvage pathway by reducing methylation drain

Stacking Synergies

+
Semax
Enhances metabolic efficiency and fat oxidation
+
P21
Improves muscle preservation and supports recomposition during caloric restriction
+
Cartalax
Supports mitochondrial output and recovery during metabolic stress

Lifestyle & Optimization

diet

Balanced protein-forward diet. Consider complementary NAD+ precursors (NMN/NR).

sleep

Prioritize sleep and stress management.

timing

Take orally with food for enhanced absorption.

exercise

Combine resistance and aerobic activity.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
Nature Medicine (2014) — Nicotinamide N-methyltransferase knockdown protects against diet-induced obesityReference
PMC (2024) — Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctionsReference
Frontiers in Pharmacology (2024) — NNMT: a novel therapeutic target for metabolic syndromeReference
PubMed (2021) — LC-MS/MS assay for 5-amino-1-methylquinolinium: pharmacokinetic and oral bioavailability studyReference
ResearchGate (2021) — Combined NNMT inhibition and reduced-calorie diet normalizes body composition in obese miceReference
PMC (2022) — Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO miceReference
NMN.com / Scientific Reports — Role of NNMT inhibition in muscle strength: enhanced grip strength with exerciseReference
Swolverine — 5-Amino-1MQ mechanism, benefits, stacking and cycling guideReference
Journal of Medicinal Chemistry (ACS) — Bisubstrate inhibitors of NNMT with enhanced activityReference
PMC — NNMT: a bad actor in fat makes good in liverReference

Side Effects & Safety

Common Side Effects

• Nausea, especially at doses above 100 mg/day
• Fatigue, lethargy, drowsiness
• Dizziness, headache
• Sleeplessness if not taken in morning

Contraindications & Warnings

• Sedation severe enough to require napping at high initial doses (user-reported)
🧬

Bioavailability & Absorption

SubQ Injection
Not applicable
Oral Administration
High oral bioavailability; enhanced when taken with food due to lipophilic properties
Intranasal
Not applicable
Half-Life
Not precisely defined in humans; estimates suggest moderate duration of action based on dosing frequency
Degradation
Metabolized hepatically and excreted renally
Tissue Specificity
Targets white adipose tissue and skeletal muscle mitochondria
⚗️

Peptide Details

Molecular Weight
138.17
Formula
C7H10N2O
⚖️

Legal Status & Regulatory

RegionStatus
EUNot Approved
FDANot Approved
CanadaNot Approved
AustraliaNot Approved

Storage Instructions

Lyophilized (Powder)
freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks